D14Ertd668e Inhibitors
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, specifically impedes the p38 MAPK pathway. By suppressing the phosphorylation of p38 MAPK, it indirectly influences PHF11d's activity. The p38 MAPK pathway intersects with PHF11d's signaling, and inhibition of this pathway alters the downstream effects, modulating PHF11d's nuclear functions and gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, disrupts the PI3K/AKT pathway. Its action inhibits the phosphorylation of AKT, indirectly affecting PHF11d. As AKT is involved in the regulation of PHF11d, the perturbation of the PI3K/AKT pathway by LY294002 leads to alterations in PHF11d's nuclear functions and gene expression patterns. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, specifically targets the JNK signaling pathway. Inhibition of JNK phosphorylation disrupts the pathway, indirectly influencing PHF11d. Since JNK interacts with PHF11d, SP600125 alters the signaling dynamics, leading to changes in PHF11d's activity and nuclear functions. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an inhibitor of NF-κB activation, disrupts the canonical NF-κB signaling pathway. By preventing IκBα phosphorylation, it indirectly affects PHF11d's function. NF-κB intersects with PHF11d, and inhibition of this pathway by BAY 11-7082 modulates PHF11d's nuclear activity, influencing gene expression patterns. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K/AKT pathway. Its inhibition alters the phosphorylation of AKT, indirectly influencing PHF11d. Since AKT is intricately linked to PHF11d regulation, Wortmannin serves as an indirect inhibitor by modulating the PI3K/AKT pathway, leading to changes in PHF11d's nuclear functions and gene expression patterns. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK1 inhibitor, disrupts the MAPK/ERK pathway. Its action inhibits the phosphorylation of downstream effectors, indirectly affecting PHF11d. Given the interplay between the MAPK/ERK pathway and PHF11d, PD98059 serves as an indirect inhibitor by modulating the signaling cascade, leading to alterations in PHF11d's activity and nuclear localization. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541, an inhibitor of the non-canonical NF-κB pathway, disrupts NF-κB signaling. Through inhibition of the phosphorylation of IKKα, it indirectly affects PHF11d's function. Since NF-κB intersects with PHF11d, BMS-345541 modulates PHF11d's nuclear activity, influencing gene expression patterns. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511, a derivative of LY294002, acts as a PI3K inhibitor. Its action disrupts the PI3K/AKT pathway, leading to alterations in the phosphorylation of AKT and indirectly affecting PHF11d. As AKT is intricately linked to PHF11d regulation, LY303511 serves as an indirect inhibitor by modulating the PI3K/AKT pathway, influencing changes in PHF11d's nuclear functions and gene expression patterns. | ||||||